Insider · CIK 0001840056

Jones Cecilia

Reports to the SEC for 2 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001840056

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	9,000
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Financial Officer	AAward	+3,000 sh	—	—	3,000
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+8,500 sh	—	—	58,139
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−3,141 sh	$34.71	−$109K	54,998
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−8,500 sh	—	—	8,500
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	39,394
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−594 sh	$28.96	−$17.2K	38,800
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,666 sh	—	—	44,466
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−1,681 sh	$28.96	−$48.7K	42,785
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+4,000 sh	—	—	46,785
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−1,187 sh	$28.96	−$34.4K	45,598
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,303 sh	—	—	50,901
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−1,573 sh	$28.96	−$45.6K	49,328
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	0
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,666 sh	—	—	5,667
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−4,000 sh	—	—	8,000
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,303 sh	—	—	10,607
2026-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Financial Officer	AAward	+14K sh	—	—	14,000
2026-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Chief Financial Officer	AAward	+52K sh	—	—	52,000
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,000 sh	—	—	40,326
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−2,932 sh	$27.09	−$79.4K	37,394
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,000 sh	—	—	0
2025-09-26	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,472 sh	—	—	37,521
2025-09-26	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−3,651 sh	$36.77	−$134K	33,870
2025-09-26	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,472 sh	—	—	0
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+6,000 sh	—	—	31,829
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−1,780 sh	$33.54	−$59.7K	30,049
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−6,000 sh	—	—	6,000
2025-03-03	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−594 sh	$35.54	−$21.1K	21,843
2025-03-03	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−1,681 sh	$35.54	−$59.7K	25,829
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	22,437
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,667 sh	—	—	27,510
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Financial Officer	AAward	+12K sh	—	—	12,000
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Financial Officer	AAward	+15.9K sh	—	—	15,910
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Chief Financial Officer	AAward	+43.5K sh	—	—	43,500
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	2,000
2025-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,667 sh	—	—	11,333
2024-09-26	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,473 sh	—	—	22,700
2024-09-26	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−2,542 sh	$49.03	−$125K	20,158
2024-09-26	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−7,473 sh	—	—	7,472
2024-03-05	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−672 sh	$32.57	−$21.9K	14,840
2024-03-01	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,000 sh	—	—	15,512
2024-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Financial Officer	AAward	+17K sh	—	—	17,000
2024-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Chief Financial Officer	AAward	+60K sh	—	—	60,000
2024-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,000 sh	—	—	4,000
2024-01-24	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−1,886 sh	$21.64	−$40.8K	13,069
2024-01-20	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,380 sh	—	—	14,955
2024-01-20	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,380 sh	—	—	0
2023-09-28	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Financial Officer	SSale	−2,179 sh	$24.79	−$54K	9,575
2023-09-26	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+7,472 sh	—	—	11,754

Recent filings

Accepted (ET)
Jun 234
Jones Cecilia0001439222-26-000083
SEC(opens sec.gov)
Apr 64
Jones Cecilia0001439222-26-000063
SEC(opens sec.gov)
Mar 34
Jones Cecilia0001439222-26-000038
SEC(opens sec.gov)
Jan 24
Jones Cecilia0001439222-26-000002
SEC(opens sec.gov)

Companies

Address

C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET

CAMBRIDGE, MA, 02139